BMJ Open Ophthalmology is an esteemed, open-access journal dedicated to the field of ophthalmology, published by the renowned BMJ Publishing Group. Established in 2016, this journal has quickly made its mark within the ophthalmology community, achieving a respectable Q2 ranking in the 2023 category quartiles. It is indexed in Scopus, boasting a commendable ranking of **#52** out of **137** in the medicine discipline of ophthalmology, placing it in the **62nd percentile**. This global platform is committed to disseminating high-quality research, clinical studies, and innovative practices that propel the understanding and treatment of eye diseases. With its open access model, BMJ Open Ophthalmology ensures that vital research is readily available to health professionals, researchers, and students, fostering collaboration and advancing knowledge within the field. The journal is based in London, United Kingdom, and continues to welcome submissions that explore the latest advancements in ophthalmic science, contributing to enhanced patient care and outcomes.

RMD Open, published by the BMJ Publishing Group, is a leading open-access journal that has made significant contributions to the fields of Immunology, Immunology and Allergy, and Rheumatology since its inception in 2015. With an impressive Q1 ranking in these categories for 2023, the journal has established itself as an essential platform for the dissemination of high-quality research, case studies, and reviews that advance understanding and treatment strategies in these critical areas of health. As an open-access publication, RMD Open ensures that its content is freely accessible to a global audience, promoting collaboration and knowledge sharing among researchers, clinicians, and students. Based in the United Kingdom at the British Medical Association House, RMD Open is not only dedicated to improving patient care but also to fostering innovative research and discussions in the rapidly evolving landscape of rheumatic diseases.

JAMA Ophthalmology, the premier journal in the field of ophthalmology, is published by the esteemed American Medical Association. Renowned for its rigorous peer-review process and commitment to advancing eye health research, JAMA Ophthalmology holds a prestigious position in the scientific community, boasting an impressive impact factor and ranking as Q1 in the category of Ophthalmology. With a Scopus rank of #3 out of 137 in its field and a remarkable 98th percentile, the journal serves as an invaluable resource for researchers, healthcare professionals, and students dedicated to the ophthalmic sciences. Readers can explore a wealth of cutting-edge findings, clinical studies, and review articles that not only contribute to the sustainable advancement of ophthalmic knowledge but also foster innovative approaches in patient care. As we converge into 2024, the journal continues to embrace open access principles, ensuring that groundbreaking research is readily available to a global audience, enhancing collaborative efforts and furthering the development of the ophthalmology discipline.

The Journal of the Korean Ophthalmological Society, with ISSN 0378-6471 and E-ISSN 2092-9374, is a pivotal resource in the field of ophthalmology, published by the esteemed Korean Ophthalmological Society. Based in South Korea, this journal is committed to advancing knowledge in ophthalmology through the dissemination of research that spans both clinical and experimental studies. Despite its current Q4 ranking in the 2023 Ophthalmology category, it serves as a crucial platform for emerging scholars, practitioners, and students seeking to contribute to and learn from the latest developments in eye care. While the journal does not currently offer open access, it is dedicated to fostering scientific dialogue and innovation within the community. With convergence years from 2018 to 2024, the journal's focus on contemporary issues in ophthalmology positions it as a relevant and timely source of information, critical for those engaged in this dynamic field. For further inquiries, the journal can be contacted at their address in Seoul, South Korea: SKY 1004 BLDG 701, 50-1 Jungnim-ro, Jung-gu, 04508.

BMC Ophthalmology is a premier open access journal dedicated to advancing the field of ophthalmology through the publication of high-quality, peer-reviewed research. Published by BMC in the United Kingdom, this journal has been a vital resource since its inception in 2001 and continuously contributes to the global dialogue in vision science. With an impact factor reflecting its growing influence, BMC Ophthalmology is ranked among the top quartiles (Q2) in both general medicine and ophthalmology, emphasizing its significance in medical research. The journal encourages submissions that explore innovative diagnostics, treatment approaches, and understandings of various ocular diseases, thereby appealing to researchers, clinicians, and students alike. As an open access platform, it ensures that cutting-edge research is not only published but also readily accessible to a worldwide audience, promoting further study and collaboration in this essential area of medicine.

JOURNAL OF GLAUCOMA is a premier academic journal dedicated to the field of ophthalmology, specializing in glaucoma research and management. Published by Lippincott Williams & Wilkins, this journal plays a pivotal role in disseminating cutting-edge research findings, clinical advancements, and evidence-based practices that address the challenges associated with glaucoma. With an impressive impact factor and categorized in the Q1 quartile in Ophthalmology as of 2023, the journal ranks #38 out of 137 in the Medicine – Ophthalmology category, placing it in the 72nd percentile amongst its peers. Since its inception in 1992, the journal has provided a vital forum for both emerging and established researchers, combining innovative studies with practical insights to enhance patient care. Although the journal is not open access, it remains committed to reaching a wide audience of professionals and students, ensuring they stay abreast of the latest developments in the field. For researchers and practitioners alike, JOURNAL OF GLAUCOMA is an essential resource for advancing knowledge and practices in glaucoma management.

Prostate Cancer is a leading peer-reviewed Open Access journal published by HINDAWI LTD, dedicated to advancing the field of urology and oncology through high-quality research and innovative studies. Established in 2011, this journal serves as a vital platform for disseminating findings related to prostate cancer diagnostics, treatment strategies, and patient care, striving to collaborate and connect researchers from around the globe. With an impact factor reflective of its critical input in the scientific community, the journal showcases compelling manuscripts, reviews, and case reports that are accessible to a wide audience given its open access policy. Located in London, England, Prostate Cancer has made significant strides in its category quartiles, achieving Q4 in Cancer Research and Q3 in both Oncology and Urology as of 2023, reflecting its growing relevance and readership. With Scopus rankings indicating its position within the broader medical fields, the journal is a valuable resource for researchers, professionals, and students alike, contributing to the collective effort to improve outcomes in prostate cancer research and treatment.

Seminars in Ophthalmology is a prestigious journal published by Taylor & Francis Inc, dedicated to advancing knowledge in the field of ophthalmology and related medical areas. Established in 1986, this journal has consistently provided a platform for high-quality research and insights, supporting the community with its impactful publications. With an impressive ranking of #55 out of 137 in the Ophthalmology category, the journal currently holds a Q2 quartile in both ophthalmology and miscellaneous medicine as of 2023, reflecting its significant contribution to the discipline. Researchers and practitioners can access a wealth of information covering a comprehensive range of topics, bolstering both clinical practice and academic inquiry. While not an open-access publication, Seminars in Ophthalmology remains a crucial resource for advancing ophthalmic research, fostering collaboration, and disseminating valuable findings in a rapidly evolving specialty.

The Journal of Translational Internal Medicine is a renowned platform dedicated to advancing the field of internal medicine through the dissemination of high-quality research and innovative clinical practices. Published by SCIENDO, this journal boasts a respectable Q2 ranking in the Internal Medicine category and is placed in the 69th percentile among its peers, highlighting its significant contribution to the discipline. With its ISSN 2450-131X and E-ISSN 2224-4018, the journal offers an open-access format, promoting accessibility to vital research findings for professionals and scholars around the globe. Located in Poland, the journal has been a valuable resource since its inception in 2018, and it continues to thrive through 2024 and beyond, supporting the objective of translating research into practice, enhancing patient care, and fostering collaboration among researchers and healthcare providers. This makes it an essential read for anyone invested in improving medical outcomes and understanding the evolving challenges faced in internal medicine.

Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.